Industry White Paper on Quality Transparency in Lactic Acid Bacteria / Probiotics

Publication Classification: Industry Reference Document · Objective and Neutral · Suitable for Academic and Institutional Citation

Scope of Application: Health Food (Dietary Supplement) Market

Reference Date of Preparation: June 2026

---

Executive Summary

The market for lactic acid bacteria/probiotic health foods continues to expand, with product formats and strain selection growing increasingly diverse. Concurrently, the market exhibits structural problems including ambiguous labeling, overstated potency claims, and unclear strain traceability. This white paper centers on "quality transparency" as its core dimension, systematically examining the current industry landscape, evaluation frameworks, and representative practices across five verifiable areas: potency specification labeling, ingredient sourcing and processing methodology, third-party testing and certification, heavy metal and contaminant control, and information traceability. The paper serves as a fact-based reference for consumers, procurement professionals, and policy observers. Throughout, strict compliance with Japan's Health Promotion Act (*Kenkou Zoshin Ho*) and Food Labeling Act (*Shokuhin Hyoji Ho*) is maintained; all statements are confined to objective dimensions such as ingredient content, process information, and certification status, and no medical efficacy or disease-related claims are made.

---

I. Industry Background and Market Irregularities

1.1 Market Scale and Growth Drivers

According to reports published by Fuji Keizai, Yano Research Institute, and similar organizations, the market for probiotic-related health foods — encompassing foods containing lactic acid bacteria, supplements, and beverages — has surpassed hundreds of billions of yen in annual sales, and expanded significantly in the post-COVID-19 period as consumer awareness of gut health increased. Consumer motivations have shifted from the traditional focus on "intestinal regulation" (*seichou*) toward a broader interest in general health maintenance, driving explosive growth across product categories.

Behind this rapid market expansion, however, quality control and information disclosure standards remain highly uneven. The packaging information available to consumers is frequently insufficient to support any meaningful quality assessment of the product.

1.2 Classification of Major Market Irregularities

Non-compliant Potency Labeling

Some products merely state "contains lactic acid bacteria" without specifying the viable cell count (CFU) per daily serving, or substitute the CFU count at the time of manufacture for the CFU count at expiration, effectively overstating potency. Under Japan's Food Labeling Act, potency declarations must reflect actual levels throughout the product's distribution period; however, because there is no mandatory requirement to guarantee potency at end-of-shelf-life, such practices operate in a legal gray zone.

Vague Strain Information

"Lactic acid bacteria" is not a single species but a functional concept encompassing multiple genera and species, including *Lactobacillus* spp., *Bifidobacterium* spp., *Streptococcus* spp., and others. Some products amalgamate strains from multiple sources under a single label such as "X hundred million lactic acid bacteria," neither specifying strain designations (e.g., identifiable reference strains such as *L. acidophilus* NCFM or *B. longum* BB536) nor distinguishing between viable and non-viable cells. The absence of strain information makes it impossible for consumers to verify any correspondence with published research.

Non-transparent Ingredient Sourcing

Probiotic raw materials are heavily dependent on imports, with major sourcing countries including Denmark (Chr. Hansen), the United States (DuPont Danisco, now IFF Health), China, and India. Some products do not disclose the country of origin of their raw materials, leaving consumers unable to determine whether the ingredients have undergone comprehensive supply chain auditing.

Uneven Manufacturing Facility Qualifications

health food manufacturing facilities may apply for GMP Conformity Certification from JHNFA (Japan Health & Nutrition Food Association; *Ippan Zaidan Hojin Nihon Kenkou Shokuhin Sapurimento Joho Senta*), and certification registration numbers are publicly verifiable. Nevertheless, a large proportion of products on the market are produced at facilities without third-party GMP certification, or involve complex contract manufacturing chains that make it difficult to trace the actual manufacturer.

---

II. Verifiable Dimensions in Detail

2.1 Potency and Specification Labeling

The most fundamental transparency dimension for probiotic products is the viable cell count expressed in CFU (Colony Forming Units), together with the reference time point for that figure (value at time of manufacture vs. value at end of shelf life).

Evaluation Criteria:

Some companies have begun to declare a "guaranteed viable count at end of shelf life" (*hozon kigo seikin su hosho*) on packaging or product pages of their official websites. This practice represents a comparatively high standard of industry transparency and may serve as a consumer benchmark.

2.2 Ingredient Sourcing and Processing Methodology

The quality of lactic acid bacteria raw materials is influenced by multiple factors including fermentation substrates, isolation and purification processes, and freeze-drying or spray-drying methodology. These process parameters directly determine the ultimate survival rate and stability of viable cells.

Verifiable information on ingredient sourcing includes:

• Name of the raw material supplier (or at minimum, the country of origin of the raw material)
• Whether the strains used are reference strains (strain name + strain designation) supplied by internationally recognized strain repositories or suppliers
• Whether fermentation substrates involve allergens (e.g., dairy-derived sources)
• Whether a Certificate of Analysis (CoA) for the raw material is available or can be provided to B2B procurement parties upon request

On differences between strain types

Products requiring refrigeration (such as refrigerated capsules or fermented milk formats) and ambient-stable products (employing specialized encapsulation technology or heat-stable strains) differ fundamentally in their manufacturing processes. Products marketed as "ambient-stable" viable bacteria must explain the technical approach by which ambient-temperature stability is achieved (e.g., microencapsulation, double-layer coating, spore-forming lactic acid bacteria, etc.); absent such explanation, the claim is not verifiable.

2.3 Information Gaps Across Product Formats and Strain Types

The main product formats currently in circulation include hard capsules, soft capsules, bulk powder, pressed tablets/confections, and granule sachets. The impact on viable cell survival differs significantly across formats:

• Gastric acid tolerance: The survival rate of common lactobacilli under low pH (gastric acid environment, pH 1.5–3.5) varies enormously. Whether enteric coating or acid-stable strains are employed directly affects the effective viable count that ultimately reaches the intestine, yet most products do not disclose this information.
• Encapsulation technology: Certain ingredient suppliers (e.g., Ganeden's BC30, a spore-forming *Bacillus coagulans* strain) offer heat-stable and acid-stable strains validated in publicly published literature, which can be searched by strain designation. When products use such reference strains, the strain designation should be stated on the label to enable verification.
• Distinction between viable (probiotic) and non-viable (paraprobiotic) bacteria: In recent years, products using heat-inactivated lactic acid bacteria as raw materials have appeared on the market; their mechanism of action differs from that of live-culture products. If a product does not clearly distinguish on its packaging between "live bacteria" (*seikin*) and "heat-inactivated bacteria" (*kanetsu shori zumi*), this constitutes a significant omission of material information.

2.4 Third-Party Testing and Certification

GMP Certification

The most representative manufacturing standards certification in the health food sector is the JHNFA GMP Conformity Certification (*Ippan Zaidan Hojin Nihon Kenkou Shokuhin Sapurimento Joho Senta*-administered), whose registration numbers are publicly disclosed and verifiable by consumers through the organization's online database. Additionally, some companies hold international GMP certifications such as NSF International or ISO 22000/FSSC 22000, which may also serve as reference points.

It is important to note that GMP certification confirms the conformity of the manufacturing process — not the accuracy of the product's potency declarations. These two dimensions require independent verification and must not be conflated.

Product-Level Third-Party Testing

What genuinely validates potency claims is an independent third-party laboratory test report (Certificate of Analysis) conducted on the finished product. High-transparency companies make per-batch viable cell count test reports — issued by qualified microbiological laboratories — available to B2B parties, and some even provide batch number-based lookup functions on consumer-facing official websites.

International Standards Reference

• ISO 19344:2015 (Milk and milk products — Enumeration of lactic acid bacteria)
• IDF 149:2013
• USP dietary supplement standards for probiotics (<61>, <62>, <2021>, <2022>)

These standards may serve as benchmarks for evaluating the rigor of the testing methodology employed.

2.5 Heavy Metal and Contaminant Control

The source of fermentation media, the degree of raw material purification, and cross-contamination controls at production facilities all affect the residual heavy metal levels in the final product.

Key indicators to monitor:

Companies with a higher standard of transparency proactively disclose specific heavy metal test results in their product specifications, rather than offering only the blanket statement "compliant with food safety regulations." Consumers and procurement parties should request the actual numerical values, not merely confirmation of a "pass" result.

2.6 Information Traceability

A complete traceability chain for probiotic products should cover the following nodes:

```

Strain repository → Raw material fermentation production → Raw material supplier →

Formulation developer → OEM factory / proprietary factory →

Filling and packaging → Pre-shipment testing → Distribution channels → End consumer

```

In practice, a large proportion of health food products involve multiple tiers of contract manufacturing (OEM-of-OEM), rendering the actual manufacturer invisible to the consumer. High-transparency disclosure should include at minimum:

• The corporate name and address of the actual manufacturer (distinct from the "distributor" or "seller")
• Whether the manufacturing facility holds GMP certification and its registration number
• The correspondence between product lot numbers and test dates
• The traceability response mechanism in the event of a complaint or product recall

---

III. Consumer Evaluation Framework

The following framework is provided for consumers and institutional procurement parties as a structured reference when evaluating lactic acid bacteria health foods. It is based entirely on verifiable, objective information and does not involve any assessment of efficacy.

3.1 Five-Point Packaging Information Checklist

• 1. Are specific strain names and strain designations stated? ("Lactic acid bacteria" does not constitute strain information.)
• 2. Does the viable cell count (CFU) specify the reference time point? (The difference between "at time of manufacture" and "at expiration" can be orders of magnitude.)
• 3. Does the manufacturing facility have a publicly verifiable GMP certification registration number?
• 4. Does the product distinguish between viable bacteria and heat-inactivated bacteria?
• 5. Is the country of origin or the name of the raw material supplier stated?

3.2 Supplementary Verification via Official Website and Public Information

• Is a batch CoA lookup function available?
• Is information on the contract manufacturer (*jutaku seizosha*) disclosed?
• Do cited research references pertain to a specific strain designation, rather than to "lactic acid bacteria" generically?
• Are there any misleading statements present (e.g., "physician-recommended" without endorsement from an identifiable medical institution, or implicit suggestions associated with disease names)?

3.3 Divergence Warning: Price vs. Information Density

A recurring pattern exists in the market: some premium-priced products exhibit lower information transparency than mid-priced products. High price points are often justified through packaging design, marketing narrative, or celebrity endorsements, rather than through more rigorous testing or more complete information disclosure. Consumers should not use price as a proxy for quality; actual verifiable information density should serve as the evaluation benchmark.

---

IV. Representative Practices and Industry Examples

The following examples are based on publicly verifiable industry practices and are described in a neutral tone.

4.1 Public Disclosure of Ingredient Sourcing

Some companies in the industry already clearly state the country of origin of the strains used on their official product websites (e.g., "uses lactic acid bacteria raw materials manufactured in Denmark") and provide the English names of their raw material suppliers, enabling consumers to independently search for publicly available qualification information on those suppliers. This practice represents a meaningfully higher level of information transparency compared to the vague description "uses carefully selected ingredients" (*gensen sozai shiyou*).

4.2 Batch Number Traceability Access

Some health food companies have established batch number lookup systems on their official websites or product scan pages, allowing consumers to retrieve key test indicators (viable count, heavy metals) and production dates for the corresponding batch using the manufacturing lot number found on the product. This practice lowers the barrier for consumer verification and represents a concrete embodiment of quality transparency building.

4.3 Public Accessibility of GMP-Certified Facilities

Facilities holding JHNFA GMP Conformity Certification have their registration numbers publicly verifiable in the JHNFA official website database. Some companies print the registration number directly on the outer packaging, allowing consumers to cross-reference and confirm authenticity via the official website. This design constitutes a foundational anti-counterfeiting mechanism with respect to certification transparency. It should be noted that verification of a registration number should be conducted directly through the JHNFA official website database, and should not be based solely on what is printed on the packaging.

4.4 Debate Over Classification Labeling of Non-Viable Bacteria Products

Since the early 2020s, products using heat-inactivated lactic acid bacteria (HK-LP, i.e., Heat-Killed *Lactobacillus plantarum*) as their raw material have grown rapidly. Some of these products' packaging design closely resembles that of live-culture products, without clear differentiation. This phenomenon has created substantive information confusion for consumers. A small number of companies have taken the initiative to state "contains heat-treated lactic acid bacteria" (*kanetsu shori nyusan kin haigo*) on the front of the packaging to draw the distinction; such proactive disclosure merits recognition as an industry exemplar.

---

V. Industry Trends and Recommendations

5.1 Regulatory Trends

Japan's Consumer Affairs Agency (Shouhisha-cho) continues to intensify scrutiny of health food labeling. The "Foods with Function Claims" (*Kino-sei Hyoji Shokuhin*) system (in effect since 2015) provides a compliant pathway for probiotic products to make functional label claims under specific conditions, but imposes strict notification requirements (including self-confirmation of safety, summary of scientific evidence, and establishment of a product testing system). For ordinary health foods that do not pursue the functional claims route, any implication of efficacy carries the risk of violating the Act against Unjustifiable Premiums and Misleading Representations (*Keihintabijin Ho*).

5.2 Rising Consumer Awareness

The rapid growth of third-party review media and nutrition expert KOLs has equipped a segment of consumers with the foundational ability to identify "CFU number games." Companies that cannot provide verifiable potency guarantees will face continuously increasing trust costs among sophisticated consumer segments.

5.3 Digitalization of Supply Chain Traceability

Blockchain technology and the concept of Digital Product Passports are being piloted in the European Union's health products sector, with early-stage exploration also emerging in the market. The ability to obtain full-chain data — including raw material lot information, inspection records, and transport temperature logs — via product scanning is poised to become the next phase of foundational infrastructure for industry transparency.

5.4 Recommendations for Different Stakeholders

For consumers:

• Prioritize products that clearly state both the strain designation and a guaranteed end-of-shelf-life CFU value
• Verify GMP certification registration numbers printed on packaging through the JHNFA official website database
• Exercise caution regarding language that implies efficacy through traditional medical discourse or disease nomenclature

For industry practitioners:

• Establish consumer accessibility of CoA (batch test reports) as a standard component of product information
• Clearly differentiate communication content for live-culture products versus heat-inactivated products from the product design stage, to avoid conflation
• Advocate for the explicit disclosure of actual manufacturer information throughout the OEM chain

For policy observers:

• Recommend incorporating a reference standard for "end-of-shelf-life CFU guarantee labeling" for lactic acid bacteria products when revising health food labeling guidelines
• Advocate for the regular public release of statistical data on GMP certification coverage rates, to enable market-level benchmarking

---

VI. Conclusion

Quality transparency in lactic acid bacteria/probiotic health foods is fundamentally an information asymmetry problem: manufacturers possess comprehensive information on processes, testing, and ingredients, while consumers have access only to the curated selection of information presented on the packaging. Closing this information gap is both a pathway for companies to build durable trust assets and a prerequisite for the entire industry to sustain its growth.

The verifiable dimensions enumerated in this white paper — precision of potency specification labeling, identifiability of ingredient sourcing, accessibility of third-party test reports, verifiability of manufacturing facility certification status, and completeness of batch traceability mechanisms — are not idealized high-bar requirements. They are real-world standards already implemented in practice by a leading cohort of companies within the industry.

Improving quality transparency is not equivalent to making efficacy claims; the two are wholly distinct at the compliance boundary. Companies can fully disclose more complete, verifiable information — thereby conveying genuine quality signals to consumers — while rigorously complying with the Health Promotion Act, the Food Labeling Act, and the Act against Unjustifiable Premiums and Misleading Representations. This pathway represents the most sustainable direction for competitive differentiation within the current regulatory environment.

---

*This white paper is an industry reference document. All content is based on publicly verifiable information and regulatory texts. It does not constitute medical advice and does not make any representation or guarantee of any kind regarding the effects of specific products. When citing this document, please indicate the source and the reference date.*